Abstract
Objective To study the effects of atypical antipsychotic drugs on glucose and lipid metabolism and body weight in female patients with schizophrenia. Methods 120 patients with schizophrenia were randomly divided into three groups according to the number randomized method.Group 1(olanzapine group) was treated with olanzapine, group 2(ziprasidone group) was treated with ziprasidone, group 3(risperidone group) was treated with risperidone.The total cholesterol (TC), triglyceride (TG) and body mass index (BMI) in the three groups were analyzed retrospectively. Results After treatment for 8 weeks, the fasting blood glucose of the olanzapine group and risperidone group increased significantly compared with before treatment, the differences were statistically significant(t=-2.81, P 0.05). After treatment for 8 weeks, the BMI of the olanzapine group and risperidone group had statistically significant difference compared with before treatment(t=-3.62, P 0.05). After treatment for 8 weeks, the TG, TC levels of the olanzapine group had statistically significant differences compared with before treatment (t=-3.89, P 0.05; t=-1.06, P>0.05; t=-0.55, P>0.05; t=-0.62, P>0.05). Conclusion Ziprasidone in the treatment of female first episode schizophrenia, has less influence on sugar, lipid metabolism and weight, with high compliance and more advantages compared with other atypical antipsychotics. Key words: Schizophrenia; Antipsychotics agents; Metabolism; Body weight; Female
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.